Date:	7/3/2022
Your Name:	Baruch Brenner
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ities with whom itionship or indi ws as needed)			ions/Comments (e.g., if were made to you or to tution)
			Time fr	ame: Since the ir	nitial planni	ng of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
				Time frame: p	oast 36 moi	nths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None			
1 1	Stock or stock options	[⊠] None			
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
1 3	Other financial or non- financial interests	[⊠] None			
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	7/3/2022
Your Name:	Yulia Kundel
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ities with who ationship or in ws as needed	ndicate		ions/Comments (e.g., if were made to you or to tution)
			Time fra	ame: Since the	e initial planr	ning of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
				Time frame	e: past 36 m	onths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None			
1 1	Stock or stock options	[⊠] None			
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
1 3	Other financial or non- financial interests	[⊠] None			
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	7/3/2022
Your Name:	Zoya Cohen
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	e all entities with whom you this relationship or indicate (add rows as needed)		tions/Comments (e.g., if s were made to you or to itution)
			Time frame: Since the initial pla	nning of the w	vork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None		Click the tab key to add additional r
			Time frame: past 36 i	months	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None			
1 1	Stock or stock options	[⊠] None			
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
1 3	Other financial or non- financial interests	[⊠] None			
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	7/3/2022
Your Name:	Hadar Brand
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this relati	es with whom gonship or indicates as needed)			ions/Comments (e.g., if were made to you or to tution)
			Time fran	ne: Since the in	itial planni	ng of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
	TOT CHILD ICCITII			Time frame: p	act 26 mar	aths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	типе тапте: р	ast so filoi		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022			
Your Name:	Noa Gordon			
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clin study			
Manuscript Number (if known):	JGO-22-352			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ities with who ationship or in ws as needed	ndicate		ions/Comments (e.g., if were made to you or to tution)
			Time fra	ame: Since the	e initial planr	ning of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
				Time frame	e: past 36 m	onths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022		
Your Name:	Aaron Sulkes		
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clin study		
Manuscript Number (if known):	JGO-22-352		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ities with who ationship or in ws as needed	ndicate		ions/Comments (e.g., if were made to you or to tution)
			Time fra	ame: Since the	e initial planr	ning of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
				Time frame	e: past 36 m	onths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022
Your Name:	Sara Morgenstern
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	e all entities with whom you this relationship or indicate (add rows as needed)		ions/Comments (e.g., if were made to you or to tution)
			Time frame: Since the initial planni	ng of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None		Click the tab key to add additional r
			Time frame: past 36 mor	nths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022
Your Name:	Nikolai Menasherov
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this relati	es with whom gonship or indicates as needed)			ions/Comments (e.g., if were made to you or to tution)
			Time fran	ne: Since the in	itial planni	ng of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
	TOT CHILD ICCITII			Time frame: p	act 26 mar	aths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None	типе тапте: р	ast so filoi		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022
Your Name:	Hanoch Kashtan
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ties with whor tionship or ind vs as needed)			ions/Comments (e.g., if were made to you or to tution)
			Time fra	me: Since the	initial plannii	ng of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit		None				Click the tab key to add additional r
	for this item.						
				Time frame:	past 36 mor	nths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022
Your Name:	David Groshar
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximal locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ties with w tionship o ws as need	r indicate			ions/Comments (e.g., if were made to you or to tution)
			Time fra	ame: Since	the initial	l plannir	ng of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None					Click the tab key to add additional r
				Time fra	ame: past	36 mon	ths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None					

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022
Your Name:	Liran Domachevsky
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	e all entities with whom you this relationship or indicate (add rows as needed)		tions/Comments (e.g., if s were made to you or to itution)
			Time frame: Since the initial pla	nning of the w	vork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None		Click the tab key to add additional r
			Time frame: past 36 i	months	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					

Date:	7/3/2022
Your Name:	Hanna Bernstine
Manuscript Title:	Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab locally advanced esophageal cancer using 18F-FDG PET-CT imaging: A prospective clistudy
Manuscript Number (if known):	JGO-22-352

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affect the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even medication is not mentioned in the manuscript.

		have	this rela	ties with who tionship or in ws as needed	ndicate		ions/Comments (e.g., if were made to you or to tution)
			Time fra	ame: Since the	e initial planr	ning of the wo	ork
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None				Click the tab key to add additional r
				Time frame	e: past 36 mo	onths	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None ■	
4	Consulting fees	None None	
•	Payment or honoraria for lectures, presentation s, speakers bureaus, manuscript writing or educational events	None None □	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None				
1 1	Stock or stock options	[⊠] None				
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None				
1 3	Other financial or non- financial interests	[⊠] None				
	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.					